Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Major Shareholder Sells $217,904.40 in Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) major shareholder Barry Canton sold 103,764 shares of Ginkgo Bioworks stock in a transaction on Monday, November 21st. The stock was sold at an average price of $2.10, for a total value of $217,904.40. Following the sale, the insider now owns 20,519,903 shares of the company’s stock, valued at $43,091,796.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Barry Canton also recently made the following trade(s):

  • On Wednesday, November 16th, Barry Canton sold 219,088 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.42, for a total value of $530,192.96.
  • On Monday, November 14th, Barry Canton sold 208,632 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.72, for a total value of $567,479.04.
  • On Thursday, November 10th, Barry Canton sold 186,028 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.46, for a total value of $457,628.88.
  • On Tuesday, November 8th, Barry Canton sold 193,616 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.46, for a total value of $476,295.36.
  • On Friday, November 4th, Barry Canton sold 204,906 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.51, for a total value of $514,314.06.
  • On Tuesday, November 1st, Barry Canton sold 196,308 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.77, for a total value of $543,773.16.
  • On Thursday, October 27th, Barry Canton sold 204,478 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.71, for a total value of $554,135.38.
  • On Monday, October 24th, Barry Canton sold 206,503 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.48, for a total value of $512,127.44.
  • On Thursday, October 20th, Barry Canton sold 196,721 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.47, for a total value of $485,900.87.
  • On Tuesday, October 18th, Barry Canton sold 198,051 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.64, for a total value of $522,854.64.

Ginkgo Bioworks Stock Performance

Shares of DNA stock opened at $1.98 on Friday. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $1.94 and a fifty-two week high of $12.48. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.67 and a current ratio of 11.71. The stock’s 50-day simple moving average is $2.71 and its 200-day simple moving average is $2.82.

Institutional Investors Weigh In On Ginkgo Bioworks

Large investors have recently modified their holdings of the business. Brown Advisory Inc. grew its stake in shares of Ginkgo Bioworks by 199.9% during the second quarter. Brown Advisory Inc. now owns 132,549 shares of the company’s stock worth $315,000 after acquiring an additional 88,358 shares during the last quarter. FDx Advisors Inc. purchased a new stake in shares of Ginkgo Bioworks during the first quarter worth about $150,000. Bradley Foster & Sargent Inc. CT grew its stake in shares of Ginkgo Bioworks by 7.3% during the second quarter. Bradley Foster & Sargent Inc. CT now owns 74,390 shares of the company’s stock worth $177,000 after acquiring an additional 5,035 shares during the last quarter. Verition Fund Management LLC grew its stake in shares of Ginkgo Bioworks by 28.6% during the first quarter. Verition Fund Management LLC now owns 38,581 shares of the company’s stock worth $155,000 after acquiring an additional 8,581 shares during the last quarter. Finally, FNY Investment Advisers LLC grew its stake in shares of Ginkgo Bioworks by 17.6% during the second quarter. FNY Investment Advisers LLC now owns 102,680 shares of the company’s stock worth $244,000 after acquiring an additional 15,375 shares during the last quarter. Hedge funds and other institutional investors own 53.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on DNA shares. Raymond James decreased their price objective on Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating for the company in a report on Tuesday. Morgan Stanley started coverage on shares of Ginkgo Bioworks in a report on Tuesday, October 4th. They issued an “equal weight” rating and a $5.00 target price for the company. Finally, BTIG Research reduced their target price on shares of Ginkgo Bioworks to $4.00 in a report on Thursday, November 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, Ginkgo Bioworks currently has a consensus rating of “Hold” and an average price target of $5.91.

Ginkgo Bioworks Company Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Further Reading

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.